Philip is an accomplished executive with a strong track record in biopharmaceutical companies, specializing in legal and compliance risk management. Reporting to the CEO and a key member of the BioMarin Senior Executive team, he significantly contributed to the company’s growth from a market capitalization of ~$2B to over ~$16B. Philip successfully developed and led a global compliance department, overseeing the commercial launch of six new drugs while managing a team of 100 employees across multiple countries. Known for strategic thinking and effective collaboration, he has a proven ability to align legal and compliance advice with corporate goals, ensuring robust risk management and operational excellence.
Currently, Philip is Vice President, Chief Compliance Officer at ImmunityBio, Inc. where he is launching their first FDA-approved drug. He is responsible for developing compliance and privacy programs, as well as serving as brand attorney supporting commercialization of Anktiva, indicated for non-muscle invasive bladder cancer.
Previously, as Executive Vice President, Compliance Audit Safety & Security – Chief Compliance Officer at BioMarin Pharmaceutical Inc., Philip oversaw developing and maintaining the company’s global compliance program as well as overseeing its internal audit, global security, corporate business continuity function, and the Environmental Health & Safety (EHS) department. He directed the development and implementation of compliance policies, anti-bribery programs, and internal audits. Philip managed GxP compliance and inspection efforts, product launches for rare diseases, global internal investigations, and led security and EHS programs, ensuring operational resilience and adherence to healthcare regulations. Before that as Deputy General Counsel, he managed legal matters related to product commercialization, implemented an enterprise contracts management system, and supported the General Counsel in licensing, SEC filings, litigation, IP management, and employment issues.
Before that, Philip was Assistant General Counsel at Sanofi-Aventis U.S. Inc. where he served as legal counsel to the cardiovascular commercial franchise. He played a key role in the development and marketing of blockbuster drugs such as Plavix, Lovenox, and Avapro. Notably, Philip contributed to the successful broadcast advertising campaigns for Plavix, which generated over $8B annually, alongside supporting strategies for Lovenox and Avapro, each exceeding $1B in annual sales. He ensured compliance with federal and state laws by reviewing advertising and promotional materials, evaluating grant requests, consultant arrangements, label extensions, and other marketing or medical program proposals. Philip drafted and negotiated consultant and commercial agreements for cardiovascular business and medical teams, and liaised with a joint-venture partner on legal, compliance, and procedural matters.
Earlier in his career, Philip was Associate Attorney at Sedgewick, Detert, Moran & Arnold where he managed all aspects of product liability, mass tort, tobacco, general liability, and medical malpractice cases from inception to trial. Drafted pleadings, discovery demands, affidavits, and orders; supervised document production; evaluated documents for responsiveness and privilege; conducted depositions; and appeared in court for conferences and settlements. Prior to that, Philip was Law Clerk Consultant at Pfizer Inc.
Philip has a Juris Doctorate from Brooklyn Law School and a Bachelor of Arts in History from Boston College. He has Bar Admissions in New York, Connecticut, and the United States District Court, Eastern & Southern